Novo Nordisk reports 26% sales growth in 2024, but projects lower 2025 growth of 16-24%. Full-year Wegovy sales up 86%, ...

Amgen's obesity drug AMG-513 on clinical hold; company reaffirms obesity market ambitions while advancing MariTide program ...

Johnson & Johnson has asked a federal district court to expedite its decision in a case over the company’s proposed 340B ...

Robert F. Kennedy Jr. advances toward Senate confirmation despite vaccine controversy, as key skeptic Sen. Bill Cassidy backs ...

China tensions, following US restrictions on Chinese rivals BGI and MGI. Illumina says China accounts for 7% of Q3 revenue.

Astellas is reorganizing its management team, and while it doesn't involve a change at the top as Daiichi Sankyo announced ...

At long last, the FDA approved Supernus Pharmaceuticals’ Parkinson’s disease treatment, which will be marketed as Onapgo.

Bavarian Nordic’s stock dropped around 10% on the Danish stock exchange Tuesday after reporting disappointing 2024 sales ...

Bicycle Health, a telehealth provider for opioid use disorder treatment led by Ankit Gupta, turns profitable and raises ...

Regeneron Pharmaceuticals, one of the original and longest-standing biotech companies, is entering the dividends arena for ...

Omega Therapeutics anticipates filing for bankruptcy within the next week, the epigenomic medicines company said in a filing.

Pfizer said Tuesday it raked in $63.6 billion in 2024, close to the top end of its guidance, and reaffirmed its sales goal ...